Sakar Healthcare Ltd

Stage 2 · Advancing · week 51Setup 5.1 ★ FairSolid +5.6

As of 16 Oct 2026, Sakar Healthcare is in Stage 2 — advancing, the uptrend phase, in week 51 (since 15 Oct 2025). It closed at ₹962, 19.1% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. More about the company

₹961.7
-2.81% today
₹2,111 Cr · Small cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

5.1 ★ Fair

Momentum

Steady

Edge

Solid +5.6

Setup-score rank among Stage 2 peers: #19 of 59 in Pharmaceuticals · #23 of 70 in Health Care

Is SAKAR early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-19.1%
₹351.5 lo₹1,188.4 hi
19.1% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 51
1w13w26w
Week 51 — mature, watch for distribution
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
33.3%
200 DMA: ₹721.2 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.38x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -4.9% vs MA50 +8.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-13.0%
3M
+9.6%
6M
+62.9%
YTD
+127.8%
1Y
+164.7%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #2 of 66 Stage 2 stocks in Health Care by RS. Leading the sector.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #2 of 56 Stage 2 stocks in this industry. Top tier.
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 34w
S4 51w
S2 52w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 34w → S3 8w → S4 51w → S1 5w → S2 13w → S3 5w → S2 52w current
Total tracked: 169 weeks across 7 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-14
60 appearances in last 60 days. First seen: 2026-07-15.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 51 · Vol 0.38x
2026-10-15S2
Wk 51 · Vol 0.61x
2026-10-14S2
Wk 51 · Vol 1.20x
2026-10-13S2
Wk 51 · Vol 1.56x
2026-10-12S2
Wk 51 · Vol 0.69x
2026-10-09S2
Wk 50 · Vol 1.58x
2026-10-08S2
Wk 50 · Vol 0.58x
2026-10-07S2
Wk 50 · Vol 0.40x
2026-10-06S2
Wk 50 · Vol 0.42x
2026-10-05S2
Wk 50 · Vol 1.25x
2026-10-01S2
Wk 49 · Vol 0.59x
2026-09-30S2
Wk 49 · Vol 0.36x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹1,011.7
200 DMA
₹721.2
52W High
₹1,188.4
52W Low
₹351.5
5D Low
₹951.6
Resistance levels (recent highs)
20d High
₹1,188.4
60d High
₹1,188.4
120d High
₹1,188.4
250d High
₹1,188.4
Next resistance
+23.6%
to 20d High
Ask the Market AI about SAKARAsk →
P/E (TTM)
57.6
Forward —
Earnings Growth (YoY)
+87.2%
Revenue +40.4%
ROE
+10.0%
Profit margin +12.0%
About this companyHealth Care· Pharmaceuticals

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.